We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B Turnover 34.18%
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+22.32%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
+$487M
Cap. Flow
+$166M
Cap. Flow %
7.61%
Top 10 Hldgs %
40.83%
Holding
354
New
43
Increased
102
Reduced
64
Closed
78
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
1.1 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
1.3 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
ABVX icon
Abivax
ABVX
+$46.5M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$38.5M
3
ZLAB icon
Zai Lab
ZLAB
+$38.4M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$34.8M
5
EDIT icon
Editas Medicine
EDIT
+$26M

Top Sells

Rank Stock Value
1
TERN icon
Terns Pharmaceuticals
TERN
+$48.2M
2
BEAM icon
Beam Therapeutics
BEAM
+$34.5M
3
SRRK icon
Scholar Rock
SRRK
+$20M
4
DNLI icon
Denali Therapeutics
DNLI
+$17.3M
5
CYTK icon
Cytokinetics
CYTK
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 86.67%
2 Miscellaneous 11.02%
3 Financials 2.15%
4 Real Estate 0.05%
5 Communication Services 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GH icon
301
Guardant Health
GH
$21.9B
– –
-10,000
Closed -$924K –
IMMX icon
302
Immix Biopharma
IMMX
$706M
– –
-10,000
Closed -$91.1K –
IMUX icon
303
Immunic
IMUX
$90.9M
– –
-3,000
Closed – –
ITGR icon
304
Integer Holdings
ITGR
$4.3B
– –
-8,750
Closed -$770K –
JAZZ icon
305
Jazz Pharmaceuticals
JAZZ
$13.6B
– –
-3,000
Closed -$567K –
KALA icon
306
KALA BIO
KALA
$3.64M
– –
-2,830
Closed -$24.5K –
KALV icon
307
DELISTED
KalVista Pharmaceuticals
KALV
– –
-10,000
Closed -$201K –
KPTI icon
308
CALL
Karyopharm Therapeutics
KPTI
$7.14M
– –
-205,200
Closed -$1.14M –
KPTI icon
309
Karyopharm Therapeutics
KPTI
$7.14M
– –
-136,736
Closed -$762K –
KZR icon
310
DELISTED
Kezar Life Sciences
KZR
– –
-81,933
Closed -$608K –
LEGN icon
311
Legend Biotech
LEGN
$3.7B
– –
-20,000
Closed -$362K –
LLY icon
312
Eli Lilly
LLY
$1.08T
– –
-5,060
Closed -$4.65M –
LPCN icon
313
Lipocine
LPCN
$13.9M
– –
-23,180
Closed -$185K –
LQDA icon
314
PUT
Liquidia Corp
LQDA
$3.04B
– –
-100,000
Closed -$3.77M –
MASI icon
315
DELISTED
Masimo
MASI
– –
-15,000
Closed -$2.67M –
MLTX icon
316
CALL
MoonLake Immunotherapeutics
MLTX
$863M
– –
-20,000
Closed -$373K –
MREO icon
317
Mereo BioPharma
MREO
$49.4M
– –
-150,000
Closed -$49.5K –
NBIX icon
318
Neurocrine Biosciences
NBIX
$13.8B
– –
-2,500
Closed -$329K –
NTLA icon
319
Intellia Therapeutics
NTLA
$1.6B
– –
-19,517
Closed -$250K –
NUVB icon
320
Nuvation Bio
NUVB
$1.64B
– –
-43,500
Closed -$187K –
PANW icon
321
Palo Alto Networks
PANW
$307B
– –
-1,600
Closed -$257K –
IRLA
322
IRulya Therapeutics Inc. Common Stock
IRLA
$30.5M
– –
-251
Closed -$5.08K –
IRLA
323
PUT
IRulya Therapeutics Inc. Common Stock
IRLA
$30.5M
– –
-250
Closed -$5.07K –
QURE icon
324
CALL
uniQure
QURE
$1.45B
– –
-100,000
Closed -$1.64M –
RARE icon
325
Ultragenyx Pharmaceutical
RARE
$1.47B
– –
-13,400
Closed -$333K –
10 11 12
13
14

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, ADAR1 Capital Management held 354 positions worth $2.19B, up 29% from $1.7B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

ADAR1 Capital Management deployed $166M of net new capital in Q2 2026, opening 43 new positions and adding to 102 existing holdings. Its largest new stake was Editas Medicine: 8,889,000 shares worth $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Denali Therapeutics, an estimated $17.3M trimmed.

  • ADAR1 Capital Management's largest Q2 2026 buy was Editas Medicine: 8,889,000 shares worth $28.8M.
  • ADAR1 Capital Management added most to Abivax in Q2 2026, an estimated $46.5M increase.
  • ADAR1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $17.3M.
  • ADAR1 Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $48.2M.
  • ADAR1 Capital Management's ten largest holdings make up 41% of its $2.19B portfolio in Q2 2026.
  • ADAR1 Capital Management opened 43 new positions and closed 78 in Q2 2026.
  • ADAR1 Capital Management's portfolio value rose 29% quarter-over-quarter to $2.19B.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.